Cryo-Cell International Inc Dossier
Qualitative Analysis
Business overview
Cryo-Cell International, Inc. (CCEL), founded in 1989 and headquartered in Oldsmar, Florida, is a pioneer in the cellular processing and cryogenic storage industry, recognized as the world's first private cord blood bank. The company operates through three primary reportable segments: cellular processing and cryogenic storage for family use (focusing on umbilical cord blood and tissue stem cells), the manufacture of the PrepaCyte CB Processing System units, and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. Cryo-Cell has stored over 500,000 samples from families across 87 countries. It holds prestigious FACT (Foundation for the Accreditation of Cellular Therapy) and AABB accreditations, positioning it as a quality leader in the private stem cell banking sector.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Leveraging over 30 years of experience in handling biological specimens to offer state-of-the-art biologic, reagent, and vaccine storage services to biopharmaceutical companies and healthcare institutions.
Expected impact: Diversifies the company's revenue streams beyond private family cord blood banking into third-party biopharmaceutical cold storage and distribution.
Execution of a strategic plan submitted to and accepted by NYSE Regulation to address the stockholders' deficit and net losses in recent fiscal years.
Expected impact: Aims to restore compliance with continued listing standards and secure the company's long-term public listing status.
Proposed spinoff of the Celle Corp. subsidiary (which holds the Duke License Agreement) and the opening of the Cryo-Cell Institute for Cellular Therapies to develop and administer cellular therapies.
Expected impact: If resumed, it would provide financial flexibility to fund future cellular therapy projects and transform the company into a vertically integrated cellular therapy provider.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquired Cord:Use's shares of common stock of Tianhe Stem Cell Biotechnologies, Inc. in accordance with an Asset Purchase Agreement. Tianhe is engaged in medical and life science research involving stem cells derived from umbilical cord blood units in clinical trials.
Financial impact: The investment value is periodically reviewed and has been deemed fully impaired with no active profits.
Strategic Partnerships
Granted rights to proprietary processes and regulatory data related to cord blood and cord tissue developed at Duke to support the company's expansion into cellular therapies.
Terms: Currently subject to a material legal dispute and termination notice from Duke, with further investments paused.